• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Geron Corp (NQ: GERN )

    4.110 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Geron Corp

    < Previous 1 2 3 4 5 Next >
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
    From Geron Corporation
    Via Business Wire
    Geron Corp. (NASDAQ: GERN) Near Top of Volume Charts in Friday Trading
    Via Investor Brand Network
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
    From Geron Corporation
    Via Business Wire
    Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
    From Geron
    Via Business Wire
    Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
    From Geron Corporation
    Via Business Wire
    Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron Corporation: FDA Approval Fuels Stock Price Surge
    FDA approval paves the way for Geron Corporation's rise as a leader in hematologic malignancy treatments. 
    Via MarketBeat
    Exposures Product Safety
    Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
    From Geron Corporation
    Via Business Wire
    Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron to Participate at Upcoming Investor Conferences in April
    From Geron Corporation
    Via Business Wire
    Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
    Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
    Via MarketBeat
    Exposures Product Safety
    Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Geron Corporation
    Via Business Wire
    Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
    From Geron Corporation
    Via Business Wire
    Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron to Participate in the B. Riley Securities Virtual Oncology Conference
    From Geron Corporation
    Via Business Wire
    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Geron Corporation
    Via Business Wire
    Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
    From Geron Corporation
    Via Business Wire
    Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
    From Geron Corporation
    Via Business Wire
    Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
    From Geron Corporation
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.